Natural Killer Cell‐Based Immunotherapy in Retinoblastoma: Biological Basis, Preclinical Evidence, and Translational Challenges
Pediatric Blood & Cancer · 02.11.2026
DOI: 10.1002/1545-5017.70805 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 02.11.2026. Verfasst von Abolfazl Parsi-Moud und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Kian Immune Cell Co., Tehran, Iran. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Retinoblastoma (RB) is the most common primary intraocular malignancy of childhood. Although current multimodal treatment has considerably improved survival, advanced and recurrent disease still requires enucleation in a substantial proportion of cases and carries long‐term psychosocial consequences. RB is driven primarily by biallelic inactivation of the RB1 tumor suppressor gene, together with secondary molecular and epigenetic alterations. A growing body of evidence indicates that RB tumors, particularly poorly differentiated and invasive forms, downregulate HLA Class I expression and antigen‐processing machinery, a phenotype that favors escape from cytotoxic T‐cell surveillance while creating a biological context that may favor natural killer (NK) cell‐mediated recognition through missing‐self mechanisms. Preclinical studies consistently show that NK and NK‐like effector cells can lyse RB cell lines and enhance antibody‐dependent cellular cytotoxicity when combined with anti‐GD2 antibodies or chemotherapy, but clinical evidence remains extremely limited, with only a single heterogeneous pilot trial reported to date and no dedicated prospective studies in RB. This review critically synthesizes the biological rationale, preclinical evidence, and clinical/immunogenetic data for NK cell‐based immunotherapy in RB and addresses the translational barriers unique to the intraocular environment, including uncertainties in immune cell trafficking across the blood–retinal barrier, delivery‐route selection, and cell‐manufacturing constraints. We conclude by proposing which RB subgroups, therapeutic platforms, and delivery strategies are most realistic for early clinical development, positioning NK cell‐based therapy as a biologically rational adjunct rather than a replacement for current treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Research and Development, Kian Immune Cell Co., Tehran, Iran.
- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Abolfazl Parsi-Moud, Parisa Shams, Marzieh Ebrahimi, Mohammad Faranoush
Zitieren
APA
Parsi-Moud, A., Daneshjou, D., Shams, P., Ebrahimi, M., & Faranoush, M. (2026). Natural Killer Cell‐Based Immunotherapy in Retinoblastoma: Biological Basis, Preclinical Evidence, and Translational Challenges. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70805
Vancouver
Parsi-Moud A, Daneshjou D, Shams P, Ebrahimi M, Faranoush M. Natural Killer Cell‐Based Immunotherapy in Retinoblastoma: Biological Basis, Preclinical Evidence, and Translational Challenges. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70805
BibTeX
@article{ParsiMoud2026,
author = {Parsi-Moud, Abolfazl and Daneshjou, Delbar and Shams, Parisa and Ebrahimi, Marzieh and Faranoush, Mohammad},
title = {Natural Killer Cell‐Based Immunotherapy in Retinoblastoma: Biological Basis, Preclinical Evidence, and Translational Challenges},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70805}
}
EUVIMED